
Results
11
Companies which are more than 50% undervalued based on analyst price target.
11 companies
Daiichi Sankyo Company
Market Cap: JP¥4.7t
Manufactures and sells pharmaceutical products in Japan and internationally.
4568
JP¥2,579.00
7D
2.1%
1Y
-21.8%
GNI Group
Market Cap: JP¥159.0b
Engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States.
2160
JP¥2,780.00
7D
10.9%
1Y
-11.3%
PeptiDream
Market Cap: JP¥136.8b
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
4587
JP¥1,005.00
7D
1.8%
1Y
-36.2%
Nxera Pharma
Market Cap: JP¥91.7b
Operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.
4565
JP¥982.00
7D
1.4%
1Y
14.2%
SanBio
Market Cap: JP¥77.9b
Engages in the development, production, and sale of regenerative cell medicines for the central nervous system.
4592
JP¥1,012.00
7D
5.7%
1Y
-53.4%
Heartseed
Market Cap: JP¥38.2b
Develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure.
219A
JP¥1,581.00
7D
8.5%
1Y
-41.7%
Healios K.K
Market Cap: JP¥34.2b
Engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
4593
JP¥257.00
7D
3.6%
1Y
-38.2%
StemRIM
Market Cap: JP¥20.3b
A biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally.
4599
JP¥319.00
7D
4.6%
1Y
6.7%
Kidswell Bio
Market Cap: JP¥7.0b
Develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan.
4584
JP¥144.00
7D
7.5%
1Y
-35.7%
Noile-Immune Biotech
Market Cap: JP¥5.3b
Researches and develops CAR-T cells for novel cancer immunotherapies.
4893
JP¥122.00
7D
5.2%
1Y
-31.8%
TMS
Market Cap: JP¥5.0b
Engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities.
4891
JP¥109.00
7D
7.9%
1Y
-29.2%